Deals
Regulus Therapeutics Dual Tracks PIPE, IPO
|
MicroRNA therapeutics developer Regulus Therapeutics (RGLS) announced that it has raised $25 million in a Common Stock transaction with investor AstraZeneca AB. The common stock was sold at $4.00 per share, an approximate 5% discount to the market price ($4.20) of RGLS at deal announcement.. The transaction closed on Oct. 10, 2012. This Placement was conducted concurrently with the Company's Initial Public Offering.